For Industry and Investigator Partners
- Cancer Moonshot Initiative Recipients
- Cancer Therapeutics program includes a cohesive group of scientists focused on target identification, drug discovery, development and translation to clinical trials.
- Research core capabilities in combinatorial chemistry, animal imaging, molecular pharmacology and immune monitoring
- Largest mouse biology program in the US
- Innovation groups comprised of basic and translational scientists and multi-disciplinary clinician researchers focused on translating laboratory discoveries to patient treatments
- To collaborate in basic science: https://research.ucdavis.edu/
- First of its kind, formal research partnership with Lawrence Livermore National Laboratory (LLNL)
- Partnership with Jackson Laboratories with Sacramento campus being the location of their mouse-derived tumor xenografts repository
- Home of the Explorer Project, an NCI-funded whole-body PET imaging development program
- GMP facility on Sacramento campus
- California National Primate Research Center on the Davis campus
- Conducts 50+ clinical trials per year including first-in-human and cellular therapies
- Trials in solid tumors and hematological malignancies
- Enrolls 150+ patient per year to phase I trials
- Ability to perform serial biopsies and pharmacokinetics
- Dedicated phase I infusion space
- The Sacramento Citywide Oncology Phase I (SCOPE) Program is a unique academic-community program with oncologists participating from:
- Dignity Health
- Kaiser Permanente
- Sutter Health
- Sierra Hematology & Oncology
- UC Davis Comprehensive Cancer Center (all patients are treated in the phase I unit at UC Davis)
- Conducts 150+ Phase I-III clinical trials per year
- Conducts investigator-initiated, federal, and industry trials
- Continuous federal funding for phase I and II trials through the NCI UM1 mechanism
- Lead Academic Partner Site (LAPS) for the NCI National Clinical Trials Network (NCTN)
- Engaged community network of sites through the Cancer Care Network
- Large Health Disparities Program with special emphasis on Native American, Asian and Hispanic population access to clinical trials
- For clinical research sponsors, email potential studies to HS-CancerOCRStartup. Confidentiality disclosure agreement, assessment of PI interest, feasibility questionnaires, and site qualification visits are facilitated through the OCR Startup team.
- 50+ staff members with expertise in regulatory, clinical and data management, financial analysis, and compliance
- Multi-site clinical trial monitoring and Quality assurance program
- Contract service lines
- Correlative laboratory with rapid on-site processing, storage, and shipping
- Cancer center-dedicated IDS Pharmacy embedded within infusion center
- Protocol development and IND management
- 90-day activation timelines for institutional and industry trials
 |
Mehrdad Abedi, M.D. |
 |
Oyebimpe Adesina, M.D., M.S. |
 |
Mili Arora, M.D. |
 |
Janai R. Carr-Ascher, M.D., Ph.D. |
 |
Helen Chew, M.D. Professor of Internal Medicine, Hematology and Oncology Director, Clinical Breast Cancer Program Director, Fellowship Program |
 |
Scott Christensen, M.D. Professor of Internal Medicine, Hematology and Oncology Associate Director, Hospice Program |
 |
David R. Gandara, M.D. Professor Emeritus of Internal Medicine, Hematology and Oncology Associate Director for Clinical Research, UC Davis Cancer Center Director, Thoracic Oncology Program |
 |
Adam Giermasz, M.D. Associate Professor of Internal Medicine, Hematology and Oncology Co-Director, Hemophilia Treatment Program |
 |
Rasmus Hoeg, M.D. Assistant Professor of Internal Medicine, Hematology and Oncology |
 |
Kendra Hutchinson, M.D. Professor of Internal Medicine, Hematology and Oncology |
 |
Brian Jonas, M.D., Ph.D. Associate Professor of Internal Medicine, Hematology and Oncology |
 |
Theresa Keegan, Ph.D., M.S. Professor of Internal Medicine, Hematology and Oncology |
 |
Paul Kaesberg, M.D. Professor of Internal Medicine, Hematology and Oncology |
 |
Karen Kelly, M.D. Professor of Internal Medicine, Hematology and Oncology Associate Director for Clinical Research Phase I Clinical Director |
 |
Edward Kim, M.D., Ph.D. Associate Professor of Internal Medicine, Hematology and Oncology |
 |
Primo Lara, M.D. Professor of Internal Medicine, Hematology and Oncology Director, UC Davis Comprehensive Cancer Center |
 |
Tianhong Li, M.D., Ph.D. Professor of Internal Medicine, Hematology and Oncology |
 |
Anjlee Mahajan, M.D. Assistant Professor of Internal Medicine, Hematology and Oncology |
 |
Mamta Parikh, M.D., M.S. Assistant Professor of Internal Medicine, Hematology and Oncology |
 |
Jonathan Riess, M.D., M.S. Associate Professor of Internal Medicine, Hematology and Oncology |
 |
Eve Rodler, M.D. Adjunct Associate Professor of Internal Medicine, Hematology and Oncology |
 |
Aaron Rosenberg, M.D., M.S. Associate Professor of Internal Medicine, Hematology and Oncology |
 |
Kit W. Tam, M.D. Assistant Professor of Internal Medicine, Hematology and Oncology |
 |
Joseph M. Tuscano, M.D. Professor of Internal Medicine, Hematology and Oncology |
 |
Rashmi Verma, M.D. Assistant Health Science Clinical Professor |
 |
Jeanna Welborn, M.D. Professor of Medicine, Pathology and Laboratory Medicine Medical Director, Adult Infusion Unit |
 |
Ted Wun, M.D. Associate Dean for Research Director of the UC Davis Clinical and Translational Science Center Chief of Hematology and Oncology Professor of Medicine, Pathology and Laboratory Medicine |
For translational and basic research, visit https://research.ucdavis.edu/
For clinical research, submit study offers to email HS-CancerOCRStartup@ucdavis.edu. Confidentiality disclosure agreements, assessment of PI interest, feasibility questionnaires and site qualification visits are facilitated through this team.